Sio Gene Therapies Inc. (SIOX)
(Delayed Data from OTC)
$0.48 USD
+0.01 (1.70%)
Updated Feb 7, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Sio Gene Therapies Inc falls in the month of March .
All items in Millions except EPS data.
3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | 3/31/19 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 72 | 42 | 69 | 127 |
Income After Depreciation & Amortization | 0 | -72 | -42 | -69 | -127 |
Non-Operating Income | NA | 0 | 10 | 1 | 6 |
Interest Expense | NA | 0 | 1 | 4 | 8 |
Pretax Income | NA | -72 | -33 | -72 | -129 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -72 | -32 | -73 | -129 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -72 | -32 | -73 | -129 |
Depreciation Footnote | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | 3/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -71 | -41 | -68 | -125 |
Depreciation & Amortization (Cash Flow) | NA | 1 | 1 | 1 | 2 |
Income After Depreciation & Amortization | 0 | -72 | -42 | -69 | -127 |
Earnings Per Share Data | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | 3/31/19 |
---|---|---|---|---|---|
Average Shares | NA | NA | 52.18 | 24.81 | 16.10 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.84 | -2.93 | -8.02 |
Diluted Net EPS (GAAP) | NA | -0.98 | -0.62 | -2.93 | -8.02 |
Fiscal Year end for Sio Gene Therapies Inc falls in the month of March .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | 0.00 |
Cost Of Goods | NA | NA | NA | NA | 0.00 |
Gross Profit | NA | NA | NA | NA | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 4.48 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -4.48 |
Non-Operating Income | NA | NA | NA | NA | 0.46 |
Interest Expense | NA | NA | NA | NA | 0.00 |
Pretax Income | NA | NA | NA | NA | -4.02 |
Income Taxes | NA | NA | NA | NA | 0.00 |
Minority Interest | NA | NA | NA | NA | 0.00 |
Investment Gains/Losses | NA | NA | NA | NA | 0.00 |
Other Income/Charges | NA | NA | NA | NA | 0.00 |
Income From Cont. Operations | NA | NA | NA | NA | -4.02 |
Extras & Discontinued Operations | NA | NA | NA | NA | 0.00 |
Net Income (GAAP) | NA | NA | NA | NA | -4.02 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | 73.98 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | -0.05 |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | -0.05 |